Sana In-Licenses BCMA CAR Construct from IASO/Innovent in $204 Million Deal

Sana Biotech, a Seattle company that creates engineered cells as medicines, acquired non-exclusive rights to a BCMA CAR construct from IASO Bio and Innovent in a $204 million agreement. Sana will have rights to use the construct in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications. IASO Bio and Innovent will receive an unspecified upfront payment and up to $204 million in milestone payments for up to six products, plus royalties. Sana will develop gene and/or cell therapies for multiple myeloma, which is also the target for the IASO/Innovent CAR-T candidate. More details.... Stock Symbols: (NSDQ: SANA) (HK: 01801) Share this with colleagues: // //